Joincare Pharmaceutical Group Industry Co Ltd
Joincare Pharmaceutical Group Industry Co.,Ltd. engages in the research, development, production, and sale of pharmaceuticals and health care products in China. The company offers chemical pharmaceuticals for respiratory, gastroenterology, assisted reproduction, psychiatry, and anti-infection; chemical APIs and intermediates for drugs for humans and veterinary drugs; and traditional Chinese medic… Read more
Joincare Pharmaceutical Group Industry Co Ltd (600380) - Total Assets
Latest total assets as of September 2025: CN¥36.01 Billion CNY
Based on the latest financial reports, Joincare Pharmaceutical Group Industry Co Ltd (600380) holds total assets worth CN¥36.01 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Joincare Pharmaceutical Group Industry Co Ltd - Total Assets Trend (1997–2024)
This chart illustrates how Joincare Pharmaceutical Group Industry Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Joincare Pharmaceutical Group Industry Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Joincare Pharmaceutical Group Industry Co Ltd's total assets of CN¥36.01 Billion consist of 64.4% current assets and 35.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 41.6% |
| Accounts Receivable | CN¥4.43 Billion | 12.4% |
| Inventory | CN¥2.62 Billion | 7.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.05 Billion | 2.9% |
| Goodwill | CN¥636.34 Million | 1.8% |
Asset Composition Trend (1997–2024)
This chart illustrates how Joincare Pharmaceutical Group Industry Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Joincare Pharmaceutical Group Industry Co Ltd's current assets represent 64.4% of total assets in 2024, an increase from 52.3% in 1997.
- Cash Position: Cash and equivalents constituted 41.6% of total assets in 2024, up from 30.0% in 1997.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 1997.
- Asset Diversification: The largest asset category is accounts receivable at 12.4% of total assets.
Joincare Pharmaceutical Group Industry Co Ltd Competitors by Total Assets
Key competitors of Joincare Pharmaceutical Group Industry Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Joincare Pharmaceutical Group Industry Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Joincare Pharmaceutical Group Industry Co Ltd generates 0.44x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Joincare Pharmaceutical Group Industry Co Ltd generates $ 3.88 in net profit.
Joincare Pharmaceutical Group Industry Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.63 | 2.19 | 2.36 |
| Quick Ratio | 2.38 | 1.94 | 2.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥14.76 Billion | CN¥ 12.56 Billion | CN¥ 10.60 Billion |
Joincare Pharmaceutical Group Industry Co Ltd - Advanced Valuation Insights
This section examines the relationship between Joincare Pharmaceutical Group Industry Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.40 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -1.8% |
| Total Assets | CN¥35.72 Billion |
| Market Capitalization | $1.34 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Joincare Pharmaceutical Group Industry Co Ltd's assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Joincare Pharmaceutical Group Industry Co Ltd's assets decreased by 1.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Joincare Pharmaceutical Group Industry Co Ltd (1997–2024)
The table below shows the annual total assets of Joincare Pharmaceutical Group Industry Co Ltd from 1997 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥35.72 Billion | -1.76% |
| 2023-12-31 | CN¥36.36 Billion | +1.76% |
| 2022-12-31 | CN¥35.73 Billion | +14.87% |
| 2021-12-31 | CN¥31.10 Billion | +10.47% |
| 2020-12-31 | CN¥28.16 Billion | +10.69% |
| 2019-12-31 | CN¥25.44 Billion | +1.81% |
| 2018-12-31 | CN¥24.99 Billion | +12.49% |
| 2017-12-31 | CN¥22.21 Billion | +38.20% |
| 2016-12-31 | CN¥16.07 Billion | +16.50% |
| 2015-12-31 | CN¥13.80 Billion | +14.16% |
| 2014-12-31 | CN¥12.08 Billion | +12.46% |
| 2013-12-31 | CN¥10.75 Billion | +10.16% |
| 2012-12-31 | CN¥9.75 Billion | +10.66% |
| 2011-12-31 | CN¥8.81 Billion | +24.01% |
| 2010-12-31 | CN¥7.11 Billion | +15.65% |
| 2009-12-31 | CN¥6.15 Billion | +5.58% |
| 2008-12-31 | CN¥5.82 Billion | -3.21% |
| 2007-12-31 | CN¥6.01 Billion | +26.73% |
| 2006-12-31 | CN¥4.75 Billion | +8.05% |
| 2005-12-31 | CN¥4.39 Billion | -0.49% |
| 2004-12-31 | CN¥4.41 Billion | -0.05% |
| 2003-12-31 | CN¥4.42 Billion | +75.01% |
| 2002-12-31 | CN¥2.52 Billion | +8.42% |
| 2001-12-31 | CN¥2.33 Billion | +206.42% |
| 2000-12-31 | CN¥759.52 Million | +11.36% |
| 1999-12-31 | CN¥682.04 Million | +14.98% |
| 1998-12-31 | CN¥593.19 Million | +32.20% |
| 1997-12-31 | CN¥448.72 Million | -- |